2023 | Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial | Llovet, Josep M; Kudo, Masatoshi; Merle, Philippe; Meyer, Tim; Qin, Shukui; Ikeda, Masafumi; Xu, Ruocai; Edeline, Julien; Ryoo, Baek-Yeol; Ren, Zhenggang; Masi, Gianluca; Kwiatkowski, Mariusz; Lim, Ho Yeong; Kim, Jee Hyun; Breder, Valeriy; Kumada, Hiromitsu; ANN-LII CHENG ; Galle, Peter R; Kaneko, Shuichi; Wang, Anran; Mody, Kalgi; Dutcus, Corina; Dubrovsky, Leonid; Siegel, Abby B; Finn, Richard S | The Lancet. Oncology | 24 | | |
2024 | Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial | CHIH-HSIN YANG ; Han, Baohui; De La Mora Jiménez, Emmanuel; Lee, Jong-Seok; Koralewski, Piotr; Karadurmus, Nuri; Sugawara, Shunichi; Livi, Lorenzo; Basappa, Naveen S; Quantin, Xavier; Dudnik, Julia; Ortiz, Diego Moran; Mekhail, Tarek; Okpara, Chinyere E; Dutcus, Corina; Zimmer, Zachary; Samkari, Ayman; Bhagwati, Niyati; Csőszi, Tibor | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | | | |